news

CUPERTINO, CA, September 28, 2000 – DURECT Corporation today announced the initial public offering of 7,000,000 shares of its Common Stock at a price to the public of $12 per share. Durect Corporation’s Common Stock will be listed on the NASDAQ National Market under the symbol “DRRX” and will begin trading on September 28, 2000. […]

Cupertino, California – PRNewswire — DURECT Corporation today announced that it has filed with the Securities Exchange Commission a registration statement relating to an initial public offering of its shares of common stock. All of the shares to be offered will be sold by the Company. The net proceeds to the Company from the sale

Pharmaceutical Firm Accelerates Activities in Ear Disorders Area Cupertino, California – PRNewswire — DURECT Corporation, a pioneer in drug therapy treatments employing continuous drug delivery technology, today announced that it has acquired substantially all of the assets of IntraEAR, Inc. of Denver, CO. Specific terms of the deal were not announced. IntraEAR, Inc. was established

San Diego, California – PRNewswire — Genetronics Biomedical Ltd. (Amex: GEB; Toronto) today announced it has elected Felix Theeuwes, D.Sc., as a new member of its Board of Directors. Dr. Theeuwes is Chairman and Chief Scientific Officer at DURECT Corporation, which was established in 1998 to focus on products based on ALZA Corporation’s (NYSE: AZA

PRNewswire — DURECT Corporation, a pioneer in drug therapy treatments employing subcutaneous delivery technology, today announced the closing of a $20 million private placement of preferred convertible stock. The Series B placement led by Brookside Capital, a Bain Capital Fund, is DURECT’s second round of funding. Additional investors include J.P. Morgan Investment Management, Collinson Howe